/term/bs-payables-and-accrued-expenses/STU:D05 Deciphera Pharmaceuticals (STU:D05) Accounts Payable & Accr
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Deciphera Pharmaceuticals Inc (STU:D05) » Definitions » Accounts Payable & Accrued Expense for Financial Companies

Deciphera Pharmaceuticals (STU:D05) Accounts Payable & Accrued Expense for Financial Companies


View and export this data going back to 2019. Start your Free Trial

What is Deciphera Pharmaceuticals Accounts Payable & Accrued Expense for Financial Companies?

Accounts Payable & Accrued Expense for Financial Companies only applies to insurance companies.

Deciphera Pharmaceuticals (STU:D05) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Deciphera Pharmaceuticals Inc (STU:D05) » Definitions » Accounts Payable & Accrued Expense for Financial Companies
Comparable Companies
AVDL COLL ANIP TLRY TARO AMRX PCRX SUPN PETQ HROW ZTS XTER:MRK TSE:4502 LSE:HLN NSE:SUNPHARMA TSE:4523 TSE:4507 SZSE:000538 XSWX:SDZ HKSE:03692
Traded in Other Exchanges
DCPH:USA D05:Germany
Address
200 Smith Street, Waltham, MA, USA, 02451
Website
https://www.deciphera.com
Deciphera Pharmaceuticals Inc is a biotechnology company, which develops and manufactures kinase-inhibiting drugs for the treatment of cancers and immunological diseases. It holds a diverse pipeline of drug candidates that includes three clinical-stage and two research-stage programs. Its lead drug candidate DCC-2618 is designed to inhibit the full spectrum of mutant or amplified KIT and Pdgfra kinases that drive cancers such as gastrointestinal stromal tumors, advanced systemic mastocytosis, gliomas, and other solid tumors. In addition, it is also developing two other clinical-stage drug candidates, DCC-3014 and Rebastinib. Geographically all the operations function through the region of the United States.